Press

Freedom Biosciences Appoints Dr. David Hough as Chief Medical Officer

Nov 16 • 3 min read

Freedom Biosciences, a clinical-stage biotechnology platform developing next-generation viable and efficacious ketamine and psychedelics-based therapeutics, today announced the appointment of David Hough, MD, as Chief Medical Officer. In this role, Dr. Hough will oversee Freedom Biosciences’ clinical development programs as the company advances its pipeline of novel therapeutics for patients with mental health and addiction…

Mindset Pharma and PharmAla Biotech Enter into Exclusive Sales Agreement

Nov 16 • 3 min read

PharmAla Biotech Holdings Inc. (CSE: MDMA), a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA, and Mindset Pharma Inc. (CSE: MSET | FSE: 9DF | OTCQB: MSSTF), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical…

Algernon Pharmaceuticals Screens First Subject in Phase 1 DMT Human Stroke Study

Nov 16 • 3 min read

Algernon Pharmaceuticals Inc. (CSE: AGN | FRANKFURT: AGW0 | OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has commenced screening subjects for its Phase 1 clinical study of an intravenous formulation of AP-188 (“N,N-Dimethyltryptamine” or “DMT”) in the Netherlands. The trial will be conducted at the Centre for…

Cybin Inc. Presents CYB003 Preclinical Data at Neuroscience 2022

Nov 15 • 2 min read

Cybin Inc. (NEO:CYBN | NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics®, today announced that the Company presented a poster highlighting preclinical data for its deuterated psilocybin analog, CYB003 at Neuroscience 2022 hosted by the Society for Neuroscience (“SFN”) taking place November 12-16, 2022, in San Diego, CA. “It is exciting to…

Field Trip Announces the Launch of Freedom by Field Trip™, a First-of-Its-Kind Ketamine Therapy Program

Nov 15 • 4 min read

Field Trip Health & Wellness Ltd. (TSX-V: FTHW) a global leader in the delivery of psychedelic therapies, today launched Freedom by Field Trip™, a first-of-its-kind one-year hybrid ketamine therapy program that blends the power of psychedelic-assisted therapies with holistic wellness support such as meditations, nutrition classes, integration therapy, breathwork, somatic movement therapy, community talks, and membership…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435